Medizinische Nachrichten und Forschung

Phase 1 dose-escalation data for ZW191 reported cORR 78.6% in FRα-high and 47.4% in FRα-low/negative PROC, with median DoR not reached and grade 3 or higher TEAEs in 55%.

Network meta-analysis of 716 double-blind RCTs with 159,362 participants found fewer AE-driven discontinuations with ARB-containing regimens, while CCBs, ACE inhibitor plus CCB, and beta-blocker plus thiazide increased withdrawals vs placebo.

Approval of tebipenem pivoxil is supported by a global randomized double-blind noninferiority trial in 1,690 hospitalized adults showing comparable composite clinical and microbiologic response to IV imipenem-cilastatin for 7 to 10 days.

Prospective cohort data suggest ~7 kg gain at 1 year and ~11 kg by 4 years, with 40–50% gaining at least 10%, and early 3-month gain tracking long-term trajectory—supporting risk stratification and proactive weight management.